. Author manuscript; available in PMC: 2014 Aug 1.

Published in final edited form as: Am J Ophthalmol. 2013 May 10;156(2):283–292.e1. doi: 10.1016/j.ajo.2013.03.021

TABLE 1.

Baseline Characteristics of Patients Receiving Encapsulated Cell Intraocular Implants for Retinitis Pigmentosa

	CNTF3		CNTF4
	Low Dose	High Dose	Low Dose	High Dose
Sex
Male	14 (63.3%)	20 (46.5%)	10 (50.0%)	23 (47.9%)
Female	8 (36.4%)	23 (53.5%)	10 (50.0%)	25 (52.1%)
Race
White	18 (81.8%)	37 (86.0%)	18 (90.0%)	47 (97.9%)
Ethnicity
Non-Hispanic/Latino	19 (86.4%)	41 (95.3%)	20 (100.0%)	44 (91.7%)
Age
Mean (SD)	41.1 (10.5)	42.0 (11)	34.9 (12)	40.2 (11.8)
Median	41.0	43.0	36.0	41.5
Range	24–59	18–67	18–58	18–59

	Implant/Sham	Implant/Sham	Implant/Sham	Implant/Sham
BCVA
Mean (SD)	45.5 (11.2)/44.8 (10.4)	45.0 (10.4)/46.7 (9.1)	79.2 (7.5)/78.9 (7.2)	78.9 (6.9)/78.7 (6.4)
Median	45.9/46.1	44.9/46.8	81.0/78.8	79.5/79.5
Range	25–64/24–65	25–65/26–62	63–91/63–91	59–90/66–92
Total mac vol (mm³)
Mean (SD)	6.0 (0.8)/6.0 (0.7)	6.2 (1.0)/6.3 (1.1)	6.3 (1.3)/6.4 (1.4)	6.3 (0.8)/6.3 (0.8)
Median	6.1/6.0	6.0/6.1	6.1/6.4	6.2/6.2
Range	4.7–8.2/4.7–7.9	4.3–9.1/4.5–9.3	4.5–10.6/4.7–11.2	5.1–8.3/4.9–8.4
Electroretinogram (μV)^a
Mean (SD)	8.32 (2.8)/8.26 (3.1)	14.3 (3.0)/12.7 (3.0)	15.4 (2.3)/17.2 (2.4)	22.2 (2.4)/22.4 (2.5)
Median	8.2/8.0	13.8/10.9	15.0/21.0	21.5/21.9
Range	2.6–65.3/1.8–58.3	3.0–84.0/3.3–88.2	3.6–65/3.7–52	5.4–149/3.9–157
Visual field sensitivity (dB)
Mean (SD)	332 (502)/323 (494)	423 (488)/444 (496)	1142 (446)/1136 (424)	1007 (429)/998 (466)
Median	202/175	210/209	1053/1095	965/966
Range	31–2307/17–2247	5–1996/2–1940	538–1885/526–1875	340–2176/220–2276

BCVA = best-corrected visual acuity (letters read by Electronic Visual Acuity); CNTF3 = ciliary neurotrophic factor for late-stage retinitis pigmentosa study 3; CNTF4 = ciliary neurotrophic factor for early-stage retinitis pigmentosa study 4; Mac vol = macular volume.

White flash – Amplitude.